0001209191-21-070646.txt : 20211220
0001209191-21-070646.hdr.sgml : 20211220
20211220184919
ACCESSION NUMBER: 0001209191-21-070646
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211217
FILED AS OF DATE: 20211220
DATE AS OF CHANGE: 20211220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Patel Gautam
CENTRAL INDEX KEY: 0001738054
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38485
FILM NUMBER: 211506400
MAIL ADDRESS:
STREET 1: C/O AMNEAL PHARMACEUTICALS LLC
STREET 2: 400 CROSSING BLVD
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001723128
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
BUSINESS PHONE: (908) 947-3120
MAIL ADDRESS:
STREET 1: 400 CROSSING BOULEVARD
STREET 2: 3RD FLOOR
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Atlas Holdings, Inc.
DATE OF NAME CHANGE: 20171117
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-12-17
0
0001723128
Amneal Pharmaceuticals, Inc.
AMRX
0001738054
Patel Gautam
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD
BRIDGEWATER
NJ
08807
1
0
0
0
Class A Common Stock
2021-12-17
4
P
0
50000
4.21
A
258784
D
Class A Common Stock
12887433
I
See Footnote
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.14 to $4.35. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
/s/ Meredith Cook, Attorney-in-Fact
2021-12-20